{"id":13306,"date":"2025-09-08T12:00:00","date_gmt":"2025-09-08T16:00:00","guid":{"rendered":"https:\/\/cov19longhaulfoundation.org\/?p=13306"},"modified":"2025-09-02T11:48:29","modified_gmt":"2025-09-02T15:48:29","slug":"why-the-fda-doesnt-support-covid-boosters-forever","status":"publish","type":"post","link":"https:\/\/cov19longhaulfoundation.org\/?p=13306","title":{"rendered":"Why the FDA Doesn\u2019t Support COVID Boosters Forever"},"content":{"rendered":"\n<p class=\"has-small-font-size wp-block-paragraph\"><em>By Marty Makary, MD, and Vinay Prasad, MD, MPH (Rewritten for journal publication)<\/em>, edited: John Murphy, The COVID 19 Long-haul Foundation<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Abstract<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The U.S. Food and Drug Administration (FDA) has revised its COVID-19 vaccination policy, signaling a significant shift in its approach to booster recommendations. This article explores the rationale behind the FDA\u2019s decision to limit booster approvals to high-risk populations, the scientific and ethical considerations driving this change, and the implications for public health, vaccine confidence, and regulatory integrity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Introduction<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Since the onset of the COVID-19 pandemic, the FDA has played a central role in evaluating and authorizing vaccines to mitigate the spread and severity of SARS-CoV-2. The initial rollout of mRNA vaccines in late 2020 marked a historic achievement in biomedical science, with rapid development, deployment, and widespread uptake. However, as the pandemic evolved, so did the virus\u2014and with it, the public\u2019s response to ongoing vaccination efforts.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In 2025, the FDA announced a pivotal change: it would no longer recommend annual COVID-19 boosters for healthy individuals under the age of 65. Instead, the agency would prioritize vulnerable populations\u2014those over 65 and individuals with comorbidities or immunocompromised conditions. This decision reflects a broader reassessment of the clinical utility, public trust, and scientific rigor surrounding booster policies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The Scientific Rationale: Immunogenicity vs. Clinical Benefit<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Central to the FDA\u2019s revised framework is the distinction between immunogenicity and clinical efficacy. While early vaccine trials demonstrated robust antibody responses, the correlation between these responses and meaningful clinical outcomes\u2014such as reduced hospitalization or death\u2014has become less clear over time, particularly in low-risk populations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dr. Marty Makary, FDA Commissioner, and Dr. Vinay Prasad, Director of the Center for Biologics Evaluation and Research, emphasized that future approvals for boosters in healthy individuals will require randomized controlled trials (RCTs) demonstrating tangible clinical benefits. \u201cWe can\u2019t just extrapolate from a clinical trial from four or five years ago,\u201d Makary stated at the American Hospital Association\u2019s annual meeting. The FDA\u2019s new policy mandates that Biologics License Applications for boosters in healthy individuals must be supported by outcome-driven data\u2014not merely antibody titers.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This shift aligns the U.S. with peer nations such as Canada, the UK, and Australia, which have already limited booster recommendations to high-risk groups.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Public Trust and Vaccine Uptake<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">One of the most pressing concerns driving the FDA\u2019s decision is the erosion of public trust in vaccines. Despite the initial success of COVID-19 vaccination campaigns, booster uptake has plummeted. Less than 25% of Americans received the most recent annual booster, and uptake among children under 12 is below 10%. Even among healthcare workers\u2014once the most vaccinated demographic\u2014booster rates have declined to roughly one-third.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Makary and Prasad argue that overextending booster recommendations to low-risk populations has contributed to skepticism not only about COVID vaccines but about vaccination more broadly. \u201cThe American people were skeptical, and some of them took that skepticism to every single vaccine, which has led to some big problems,\u201d Prasad noted.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">By narrowing the scope of recommendations, the FDA aims to restore credibility and reinforce the principle of evidence-based medicine. This recalibration is not a retreat from science\u2014it is a recommitment to it.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Ethical Considerations: Risk, Benefit, and Autonomy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The ethical calculus of recommending medical interventions hinges on a balance of risks and benefits. For high-risk individuals, the benefits of COVID-19 boosters remain compelling. However, for healthy individuals\u2014particularly children and young adults\u2014the risk-benefit ratio is less favorable.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Makary posed a provocative question: \u201cShould we really be putting the full weight of the government to urge vaccination against COVID for a healthy, thin 12-year-old girl with her seventh COVID booster right now today in America? I don\u2019t think so\u201d.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This sentiment underscores a broader ethical concern: the medicalization of low-risk populations without clear evidence of benefit. The FDA\u2019s new policy respects individual autonomy while ensuring that public health recommendations are grounded in rigorous science.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Regulatory Integrity and the Role of Evidence<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA\u2019s credibility depends on its commitment to transparent, evidence-based decision-making. In recent years, critics have accused the agency of succumbing to political pressure and pharmaceutical lobbying. Makary and Prasad\u2019s policy seeks to reverse this trend by demanding \u201cgold standard science\u201d from vaccine manufacturers.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Future booster approvals will require RCTs that evaluate not just antibody levels but real-world outcomes. This approach reflects a maturation of the regulatory process\u2014one that prioritizes long-term safety, efficacy, and public trust over expediency.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">International Context and Comparative Policy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Globally, the trend toward targeted booster recommendations is well established. In the UK, boosters have been limited to vulnerable groups for several seasons. European regulators have similarly adopted risk-based frameworks, citing limited evidence for annual boosters in healthy populations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA\u2019s new policy brings the U.S. into alignment with these international standards. It also reflects a growing consensus among immunologists that repeated boosting in low-risk individuals may offer diminishing returns\u2014and could even pose risks, such as immune fatigue or adverse reactions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Implications for Future Vaccine Development<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA\u2019s revised stance has significant implications for pharmaceutical companies, clinical researchers, and public health officials. Vaccine developers will need to design trials that measure clinical endpoints, not just immunogenicity. Researchers must explore alternative strategies for long-term immunity, such as mucosal vaccines or pan-coronavirus platforms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Public health officials will need to recalibrate messaging to emphasize targeted protection rather than universal boosting. This shift may also open the door to more personalized vaccination strategies, guided by individual risk profiles and emerging biomarkers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Conclusion<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA\u2019s decision to limit COVID-19 booster recommendations marks a watershed moment in the pandemic response. It reflects a nuanced understanding of risk, benefit, and evidence\u2014and a commitment to restoring public trust in the regulatory process.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Makary and Prasad\u2019s policy is not an indictment of vaccines. Rather, it is a call for precision, integrity, and accountability. As the pandemic enters a new phase, the FDA\u2019s role must evolve from crisis management to thoughtful stewardship. That means asking hard questions, demanding rigorous data, and putting science\u2014not politics\u2014at the center of public health.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>By Marty Makary, MD, and Vinay Prasad, MD, MPH (Rewritten for journal publication), edited: John Murphy, The COVID 19 Long-haul Foundation Abstract The U.S. Food and Drug Administration (FDA) has [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":13310,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[725,761,445,607,608],"tags":[],"class_list":["post-13306","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-booster-shot","category-concerns","category-policies-politics","category-vaccine-news","category-vaccine-safety"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/13306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13306"}],"version-history":[{"count":2,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/13306\/revisions"}],"predecessor-version":[{"id":13308,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/13306\/revisions\/13308"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/13310"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}